Is surgery the gold standard in the treatment of obstructive hypertrophic cardiomyopathy? 2013

Gennady Knyshov, and Vasyl Lazoryshynets, and Kostyantyn Rudenko, and Borys Kravchuk, and Vyacheslav Beshlyaga, and Valery Zalevsky, and Olga Rasputnyak, and Bogdan Batsak
National Institute of Cardiovascular Surgery, Academy of Medical Sciences of Ukraine, Kiev, Ukraine.

OBJECTIVE Hypertrophic cardiomyopathy is a complex and relatively common genetic cardiac disease and has been the subject of intensive scrutiny and investigation for over 40 years. The aim of this non-randomized cohort study was to compare subjective and objective outcomes in hypertrophic cardiomyopathy patients undergoing drug therapy, surgical myotomy-myectomy, dual-chamber pacing and alcohol septal ablation. METHODS We examined 194 patients: 103 with non-obstructive hypertrophic cardiomyopathy and 91 with obstructive hypertrophic cardiomyopathy. All the patients with a non-obstructive form were on drug therapy. Ninety-one consecutive patients with drug-refractory obstructive hypertrophic cardiomyopathy were treated invasively. Dual-chamber pacemaker implantation was performed for 49 patients with previous positive temporary pacing test (Group 1). In 28 patients with massive left ventricle hypertrophy and obliteration of its cavities, extensive myotomy-myectomy was performed (Group 2). In 14 patients with midventricular obstruction and appropriate coronary anatomy, alcohol septal ablation was performed (Group 3). RESULTS The peak left ventricle outflow tract gradient was 84.1 ± 15.2 mmHg in Group 1, 113.3 ± 14.9 mmHg in Group 2 and 97.5 ± 8.9 mmHg in Group 3. Dual-chamber pacing in Group 1 with optimal atrio-ventricular delay (85-180 ms for atrium pacing and 45-120 ms for atrial sensing) leads to dramatic decreases in left ventricle outflow tract gradient to 17.6 ± 11.8 mmHg and degree of mitral regurgitation. After extensive myectomy in Group 2, we observed a reduction of left ventricle outflow tract gradient to 17.3 ± 10.2 mmHg. Septal alcohol ablation in Group 3 leads to a left ventricle outflow tract gradient decrease from 97.5 ± 8.9 to 25.3 ± 5.8 mmHg. CONCLUSIONS Surgical myectomy, dual-chamber pacing and alcohol septal ablation are equally effective in reducing obstruction in case of correct indications. Dual-chamber pacing is indicated in functional reversible states characterized by excitation delay. Alcohol septal ablation is preferable in cases with midventricular obstruction and appropriate coronary anatomy. Surgical methods are indicated in anatomical irreversible changes and remain the gold standard for obstructive hypertrophic cardiomyopathy treatment.

UI MeSH Term Description Entries
D008297 Male Males
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D002304 Cardiac Pacing, Artificial Regulation of the rate of contraction of the heart muscles by an artificial pacemaker. Pacing, Cardiac, Artificial,Artificial Cardiac Pacing,Artificial Cardiac Pacings,Cardiac Pacings, Artificial,Pacing, Artificial Cardiac,Pacings, Artificial Cardiac
D002312 Cardiomyopathy, Hypertrophic A form of CARDIAC MUSCLE disease, characterized by left and/or right ventricular hypertrophy (HYPERTROPHY, LEFT VENTRICULAR; HYPERTROPHY, RIGHT VENTRICULAR), frequent asymmetrical involvement of the HEART SEPTUM, and normal or reduced left ventricular volume. Risk factors include HYPERTENSION; AORTIC STENOSIS; and gene MUTATION; (FAMILIAL HYPERTROPHIC CARDIOMYOPATHY). Cardiomyopathy, Hypertrophic Obstructive,Cardiomyopathies, Hypertrophic,Cardiomyopathies, Hypertrophic Obstructive,Hypertrophic Cardiomyopathies,Hypertrophic Cardiomyopathy,Hypertrophic Obstructive Cardiomyopathies,Hypertrophic Obstructive Cardiomyopathy,Obstructive Cardiomyopathies, Hypertrophic,Obstructive Cardiomyopathy, Hypertrophic
D002317 Cardiovascular Agents Agents that affect the rate or intensity of cardiac contraction, blood vessel diameter, or blood volume. Cardioactive Agent,Cardioactive Drug,Cardiovascular Agent,Cardiovascular Drug,Cardioactive Agents,Cardioactive Drugs,Cardiovascular Drugs,Agent, Cardioactive,Agent, Cardiovascular,Drug, Cardioactive,Drug, Cardiovascular
D005260 Female Females
D006348 Cardiac Surgical Procedures Surgery performed on the heart. Cardiac Surgical Procedure,Heart Surgical Procedure,Heart Surgical Procedures,Procedure, Cardiac Surgical,Procedure, Heart Surgical,Procedures, Cardiac Surgical,Procedures, Heart Surgical,Surgical Procedure, Cardiac,Surgical Procedure, Heart,Surgical Procedures, Cardiac,Surgical Procedures, Heart
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000293 Adolescent A person 13 to 18 years of age. Adolescence,Youth,Adolescents,Adolescents, Female,Adolescents, Male,Teenagers,Teens,Adolescent, Female,Adolescent, Male,Female Adolescent,Female Adolescents,Male Adolescent,Male Adolescents,Teen,Teenager,Youths
D000328 Adult A person having attained full growth or maturity. Adults are of 19 through 44 years of age. For a person between 19 and 24 years of age, YOUNG ADULT is available. Adults

Related Publications

Gennady Knyshov, and Vasyl Lazoryshynets, and Kostyantyn Rudenko, and Borys Kravchuk, and Vyacheslav Beshlyaga, and Valery Zalevsky, and Olga Rasputnyak, and Bogdan Batsak
June 2008, Expert review of cardiovascular therapy,
Gennady Knyshov, and Vasyl Lazoryshynets, and Kostyantyn Rudenko, and Borys Kravchuk, and Vyacheslav Beshlyaga, and Valery Zalevsky, and Olga Rasputnyak, and Bogdan Batsak
April 2009, Zhonghua xin xue guan bing za zhi,
Gennady Knyshov, and Vasyl Lazoryshynets, and Kostyantyn Rudenko, and Borys Kravchuk, and Vyacheslav Beshlyaga, and Valery Zalevsky, and Olga Rasputnyak, and Bogdan Batsak
November 2004, Journal of the American College of Cardiology,
Gennady Knyshov, and Vasyl Lazoryshynets, and Kostyantyn Rudenko, and Borys Kravchuk, and Vyacheslav Beshlyaga, and Valery Zalevsky, and Olga Rasputnyak, and Bogdan Batsak
April 2014, Heart (British Cardiac Society),
Gennady Knyshov, and Vasyl Lazoryshynets, and Kostyantyn Rudenko, and Borys Kravchuk, and Vyacheslav Beshlyaga, and Valery Zalevsky, and Olga Rasputnyak, and Bogdan Batsak
December 1982, Zeitschrift fur Kardiologie,
Gennady Knyshov, and Vasyl Lazoryshynets, and Kostyantyn Rudenko, and Borys Kravchuk, and Vyacheslav Beshlyaga, and Valery Zalevsky, and Olga Rasputnyak, and Bogdan Batsak
January 2009, Cardiovascular revascularization medicine : including molecular interventions,
Gennady Knyshov, and Vasyl Lazoryshynets, and Kostyantyn Rudenko, and Borys Kravchuk, and Vyacheslav Beshlyaga, and Valery Zalevsky, and Olga Rasputnyak, and Bogdan Batsak
October 1995, Schweizerische medizinische Wochenschrift,
Gennady Knyshov, and Vasyl Lazoryshynets, and Kostyantyn Rudenko, and Borys Kravchuk, and Vyacheslav Beshlyaga, and Valery Zalevsky, and Olga Rasputnyak, and Bogdan Batsak
November 2004, Journal of the American College of Cardiology,
Gennady Knyshov, and Vasyl Lazoryshynets, and Kostyantyn Rudenko, and Borys Kravchuk, and Vyacheslav Beshlyaga, and Valery Zalevsky, and Olga Rasputnyak, and Bogdan Batsak
January 2021, Journal of the American Heart Association,
Gennady Knyshov, and Vasyl Lazoryshynets, and Kostyantyn Rudenko, and Borys Kravchuk, and Vyacheslav Beshlyaga, and Valery Zalevsky, and Olga Rasputnyak, and Bogdan Batsak
November 1987, Circulation,
Copied contents to your clipboard!